<DOC>
	<DOCNO>NCT00281970</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving chemotherapy drug surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well give docetaxel together cisplatin work treat patient stage I , stage II , stage III non-small cell lung cancer completely remove surgery .</brief_summary>
	<brief_title>Docetaxel Cisplatin Treating Patients With Stage I , Stage II , Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy safety new dose schedule dose level docetaxel cisplatin chemotherapy regimens use International Adjuvant Lung Cancer Trial ( IALT ) patient completely resect stage IA-IIIB non-small cell lung cancer . Secondary - Explore relationship time recurrence , disease-free survival , overall survival patient level circulate DNA proteomic analysis serum . OUTLINE : This open-label study . Patients receive docetaxel IV 30 minute day 1 , 8 , 15 cisplatin IV 8 hour day 15 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically prove nonsmall cell lung cancer ( NSCLC ) Stage IAIIIB disease Underwent prior complete surgical resection ( R0 ) 2 month ago Eligible cisplatinbased adjuvant chemotherapy PATIENT CHARACTERISTICS : Karnofsky performance status ≥ 70 % Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 100,000/mm^3 Creatinine clearance &gt; 55 mL/min Total bilirubin normal Alkaline phosphatase , AST , ALT must meet 1 follow criterion : Alkaline phosphatase ( AP ) normal AND AST ALT ≤ 5 time upper limit normal ( ULN ) AP ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN AP ≤ 5 time ULN AND AST ALT normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No peripheral neuropathy &gt; grade 1 No hearing deficit baseline , even require hear aid intervention interfere activity daily life ( i.e. , CTCAE grade 2 high ) PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior postoperative radiation therapy No prior chemotherapy NSCLC No prior docetaxel cisplatin No concurrent prophylactic filgrastim ( GCSF ) pegfilgrastim</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>